Medicines that hinder rather than help healing
Adding a further layer of concern is the finding that 16 of the 17 manufactures investigated are based in India, which plays a dominant role in global pharmaceutical supply chain.
Often described as 'pharmacy of the world' the country produces approximately 20 percent of the generic medicines, exporting them to more than 100 countries. A vast majority of them are low and middle income ones, including Pakistan, raising red flags about the quality of medications being consumed.
The drugs in questions, reveals the present report, form the backbone of treatment plans for numerous common cancers — including breast, ovarian and leukaemia. Some of them contained so little of their key ingredients that giving them to patients would be as good as doing nothing; other drugs in this category were composed of excessive active ingredients that put patients at risk of severe organ damage, even death.
These findings suggest cost-efficiency is prioritised at the expense of quality assurance and regulatory compliance, and call into question reliability of existing regulatory frameworks both in the exporting and importing countries. In India, while there are regulations in place under the Central Drugs Standard Control Organisation, enforcement has been inconsistent, if not shoddy.
Consequently, quality control lapses have plagued the sector for years. In 2023, Indian-made cough syrups made the news for causing death of at least 70 children in Gambia and many more in Cameroon and Uzbekistan. In August of last year, more than 50 drugs on the market, including some anti-acids and paracetamol, turned out to be substandard or fake.
Much before that in 2013, Indian manufacturer Ranbaxy paid a fine of US$ 500 million after its US subsidiary pleaded guilty to improper manufacturing, storing and testing of drugs. These examples plus the research findings of University of Notre Dame underscore the need for regulatory review and response from Pakistan.
Our health authorities, particularly the Drug Regulatory Authority of Pakistan (DRAP), must ramp up their quality assurance mechanisms, including more rigorous testing of imported drugs and reassessing licensing agreements with suspect companies.
As regards the broader issue of accountability and transparency, those involved in producing substandard medicines must be made to face meaningful consequences, such as bans, fines and blacklisting from markets. While affordable medicines are crucial, they must not come at the cost of safety and efficacy; patients everywhere deserve better than to be exposed to life-threatening risks from bad medications. Governments and regulators need to act decisively to certify that each medicine contains everything that is stated on its label.
Copyright Business Recorder, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
5 days ago
- Business Recorder
Gaza civil defence says 12 killed by Israeli forces
GAZA CITY: Gaza's civil defence agency said Israeli forces killed at least 12 people on Monday, including six in a clinic housing Palestinians displaced after 21 months of war. Israel has recently expanded its military operations in the Gaza Strip, where the war has created dire humanitarian conditions for the Palestinian territory's population of more than two million. Civil defence spokesman Mahmud Bassal told AFP that six people were killed and 15 injured in an Israeli air strike that hit the Al-Rimal clinic, 'which houses hundreds of displaced people, in the Al-Rimal neighborhood west of Gaza City.' AFP footage showed Palestinians, including groups of young children, combing through the bombed-out interior of the clinic, where mattresses lay alongside wood, metal and concrete broken apart in the blast. 'We were surprised by missiles and explosions inside the building,' eyewitness Salman Qudum told AFP. 'We did not know where to go because of the dust and destruction.' Gaza civil defence says 32 killed in Israeli operations In the south of the territory, Bassal said two people were killed and 20 others injured by Israeli forces' gunfire while waiting for aid near a distribution site run by the Gaza Humanitarian Foundation (GHF). A US- and Israel-backed group, the GHF took the lead in food distribution in the territory in late May, but its operations have had a chaotic rollout with repeated reports of aid seekers killed near its facilities. Hundreds reported killed The UN human rights office said last week that more than 500 people have been killed waiting to access food from GHF distribution points. The health ministry in Hamas-run Gaza on Sunday placed that toll higher, at 751 killed. In Khan Yunis in the south, Bassal reported two people killed in an air strike on a house and another killed by Israeli gunfire. Israeli military kills 15 in Gaza as Trump waits for Hamas response to ceasefire proposal An air strike on a house in Gaza City killed one and injured several others, he added. The Israeli military did not immediately respond to an AFP request for comment. In a separate statement, it said it had struck 'dozens of terrorists, weapons depots, observation posts, military buildings, and other terror infrastructures' over the past 24 hours. 613 killed at Gaza aid distribution sites, near humanitarian covoys, says UN Media restrictions in Gaza and difficulties in accessing many areas mean AFP is unable to independently verify the tolls and details provided by the civil defence agency. Out of 251 hostages seized during the attack, 49 are still held in Gaza, including 27 the Israeli military says are dead. Israel's retaliatory campaign has killed more than 57,418 people in Gaza, also mostly civilians, according to the Hamas-run territory's health ministry. The United Nations considers its figures reliable.
Business Recorder
05-07-2025
- Business Recorder
Medicines that hinder rather than help healing
EDITORIAL: The report that about one-fifth of generic medicines' samples tested by researchers at the University of Notre Dame failed quality control tests is deeply troubling — all the more so given an increasing public reliance on generic drugs for affordable healthcare. Adding a further layer of concern is the finding that 16 of the 17 manufactures investigated are based in India, which plays a dominant role in global pharmaceutical supply chain. Often described as 'pharmacy of the world' the country produces approximately 20 percent of the generic medicines, exporting them to more than 100 countries. A vast majority of them are low and middle income ones, including Pakistan, raising red flags about the quality of medications being consumed. The drugs in questions, reveals the present report, form the backbone of treatment plans for numerous common cancers — including breast, ovarian and leukaemia. Some of them contained so little of their key ingredients that giving them to patients would be as good as doing nothing; other drugs in this category were composed of excessive active ingredients that put patients at risk of severe organ damage, even death. These findings suggest cost-efficiency is prioritised at the expense of quality assurance and regulatory compliance, and call into question reliability of existing regulatory frameworks both in the exporting and importing countries. In India, while there are regulations in place under the Central Drugs Standard Control Organisation, enforcement has been inconsistent, if not shoddy. Consequently, quality control lapses have plagued the sector for years. In 2023, Indian-made cough syrups made the news for causing death of at least 70 children in Gambia and many more in Cameroon and Uzbekistan. In August of last year, more than 50 drugs on the market, including some anti-acids and paracetamol, turned out to be substandard or fake. Much before that in 2013, Indian manufacturer Ranbaxy paid a fine of US$ 500 million after its US subsidiary pleaded guilty to improper manufacturing, storing and testing of drugs. These examples plus the research findings of University of Notre Dame underscore the need for regulatory review and response from Pakistan. Our health authorities, particularly the Drug Regulatory Authority of Pakistan (DRAP), must ramp up their quality assurance mechanisms, including more rigorous testing of imported drugs and reassessing licensing agreements with suspect companies. As regards the broader issue of accountability and transparency, those involved in producing substandard medicines must be made to face meaningful consequences, such as bans, fines and blacklisting from markets. While affordable medicines are crucial, they must not come at the cost of safety and efficacy; patients everywhere deserve better than to be exposed to life-threatening risks from bad medications. Governments and regulators need to act decisively to certify that each medicine contains everything that is stated on its label. Copyright Business Recorder, 2025
Business Recorder
04-07-2025
- Business Recorder
Curbing diabetes surge
EDITORIAL: The federal government has pledged US$ 6.8 million over a five-year period for the 'Prime Minister's Programme for the Prevention and Control of Diabetes.' Following a meeting with key stakeholders on Tuesday, Minister for Planning, Development and Special Initiatives, Ahsan Iqbal, announced the initiative, emphasising the urgent need to address Pakistan's rapidly rising diabetes rates. The programme begins in the federal capital in its first year, expanding to the provinces from the second year onward. The goal is to reach approximately 33 million Pakistanis through screening, diagnosis, and treatment by leveraging primary healthcare facilities, lady health workers, and public awareness campaigns. While this initiative is a crucial first step, it is a relatively modest effort, given the scale of the crisis. Pakistan is among the top three countries where diabetes is spreading at an alarming rate. Surveys estimate that 28–33 percent of the urban population is affected, while about 27 percent of cases go undiagnosed. The proposed funding, which will be shared between the federal and provincial governments, covers only a fraction of what is truly needed to overhaul diabetes prevention, education, medication access, and long-term disease management. Nonetheless, it is encouraging that the majority of the target population is included within the programme's scope — an indication that the government recognises the seriousness of the issue. This approach is also in line with expert recommendations to integrate diabetes prevention into primary healthcare systems. However, it's important to address the root causes fuelling the surge in Type 2 diabetes: increasing consumption of ultra-processed foods, sugary beverages, and sedentary lifestyles. The result is a silent epidemic that leads to severe health complications such as heart disease, kidney failure, and other issues. These challenges require not only medical intervention but also effective preventive measures, including mass screening, public nutrition education, and tighter regulation of unhealthy food products — all of which should be central to the new government plan. Unfortunately, the broader context is anything but reassuring. The recent 16 percent cut in the federal health development budget undermines the government's capacity to complete essential infrastructure projects and build preventive healthcare systems. While the US$ 6.8 million programme is commendable, its success depends on sustained investment, cross-sector collaboration, and systemic reforms. To effectively stem the tide of diabetes — as well as to fight serious communicable diseases such as hepatitis, polio, and tuberculosis — the federal and provincial governments need to scale up resources and ensure universal access to screening and affordable treatment. Only through a comprehensive and well-resourced approach can this initiative become an important milestone in health equity for our people. Copyright Business Recorder, 2025
